Form 4 for ARVN ARVINAS, INC.

Accepted 2024-03-21 00:00:00 ET · period of report 2024-03-18 · accession 0001655759-24-000040 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-03-21	2024-03-18	ARVN	Berkowitz Noah	Chief Medical Off	A - Grant	$0.00	+63.5K	63.5K	New	$0
D	2024-03-21	2024-03-18	ARVN	Berkowitz Noah	Chief Medical Off	A - Grant	$0.00	+93.9K	93.9K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-03-18	A	A	63,452	$0.00	63,452	D	—	—	(F1) The restricted stock units (each, an "RSU") were granted by the Issuer on March 18, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4), and not pursuant to its 2018 Stock Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: 25% of the RSUs will vest on each of March 18, 2025, March 18, 2026, March 18, 2027 and March 18, 2028, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
2	Derivative	Stock Option (right to buy)	2024-03-18	A	A	93,879	$0.00	93,879	D	$42.60 · — to 2034-03-17	93,879 Common Stock	(F2) The option was granted by the Issuer on March 18, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant the Plan. The shares underlying the option will vest over four years: 1/4 of the shares underlying the award shall vest on March 18, 2025, with the remainder of the shares vesting in equal monthly installments following March 18, 2025 through March 18, 2028.